Synthetic Peptide | Residues | Sequence | Type of Peptide |
---|---|---|---|
CYP2D6254–273 | 254–273 | CLLTEHRM TWD PAQPPRDLTE | Linear |
CYP2D6cyclic 254–273 | 254–273 | KGCLLTEHRM TWD PAQPPRDLTEC | Cyclic |
CYP2D6cyclic 257–268 | 257–268 | KGCEHRM TWD PAQPPC | Cyclic |
CYP2D6261–272 | 261–272 | C TWD PAQPPRDLT | Linear |
CYP2D6cyclic 261–272 | 261–272 | KGC TWD PAQPPRDLTC | Cyclic |
CYP2D6263–270 | 263–270 | C D PAQPPRD | Linear |
CYP2D6278–290 | 278–290 | CEMEKAKGNPESSF | Linear |
CYP2D6cyclic 278–290 | 278–290 | KGCEMEKAKGNPESSFC | Cyclic |
Target protein sequence | 254–290 | -LLTEHRM TWD PAQPPRDLTEAFLAEMEKAKGNPESSF- | CYP2D6 protein |
The CYP2D6 amino acid sequence was predicted from its cDNA sequence and is numbered from the N-terminal methionine. The synthetic peptides are numbered with respect to human CYP2D6. The consensus core sequence of the epitope of anti-CYP2D6 antibodies identified by Manns (1991) andGueguen et al. (1991) is shown in bold. The residues of CYP2D6 identified by Gueguen et al. (1991) as essential for antibody binding are underlined. Cyclic peptides were formed by oxidation of the two cysteine residues in their sequence and then coupled to KLH through the N-terminal lysine residue (Fig. 1). Linear peptides were coupled to KLH through their N-terminal cysteine residue.